- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03546127
Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study (MULTIPLI-0)
Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study (MULTIPLI-0)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The first France disease genomic medicine program in the field of cancer has been retained by the 2025 Genomic Medicine France Plan. This program, called MULTIPLI encompasses two innovative personalized medicine clinical trials in soft-tissue sarcoma and colorectal carcinoma involving targeted molecules according to the tumor profile of each patient.
This 1st clinical research program aims implementing exome sequencing and RNA sequencing to determine the genomic profile and to provide a therapeutic decision for each patient. Genomic analyzes will be performed on different technical platforms: samples will be collected in each investigating center, nucleic acids extraction will be performed on two genetic platforms, Inca labeled and identified for the purpose of this study: Institut Bergonié and Hôpital Européen Georges Pompidou. CNRGH (Centre National de Recherche en Génomique Humaine) was retained for operational platform genomics and Institut Bergonie for bioinformatics data processing. Each genomic profile will be discussed within a multidisciplinary tumor board which aims at providing a therapeutic decision for each patient and to propose a targeted treatment in case of actionable molecular alteration.
The purpose of this program is to perform analysis on a set of gene, in order to provide results no more than after 6 weeks after the sample arrival on the biopathological platform. This gene panel analysis is based on the predefined list of genes that are direct targets of the drugs available in the MULTIPLI program.
Before implanting this program in a large-scale launch, it was essential to set up a pilot study in order to evaluate both sample's management between several platforms, and the time to report the results, and to verify that it was in line with the objectives set.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Institut Bergonié
-
Paris, France, 75000
- Hôpital Européen Georges Pompidou
-
Évry, France, 91057
- CEA / Centre National de Recherche en Génomique Humaine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients included in this prospective cohort study are patients who have previously consented to tumor sequencing either as part of others studies or as part of standard care (voluntary signed informed consent). Two participating centers have been retained.
Samples used (blood and tumor) are issued from these previous collection and analyzed for the same purpose: no additional samples will be collected.
Description
Inclusion Criteria:
- Adult patients
- Disease: Advanced and/or metastatic soft-tissue sarcoma OR metastatic carcinoma
- Patient consenting to tumor sequencing, secondary reuse of their data
- Patient informed about this study
Exclusion Criteria:
- N/A
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
STS
Patients with advanced/metastatic soft-tissue sarcoma
|
Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms. For both sequencing configurations:
|
CCR
Patients with metastatic colorectal carcinoma
|
Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms. For both sequencing configurations:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Delay time to send a validated exome sequencing report from sample receipt
Time Frame: an average of 6 weeks
|
The time delay between the date of sample receipt by the platform and the date of dispatch of a validated MTB report to physician
|
an average of 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of patients with samples received by Platform for whom a validated exome sequencing report is available
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom a report was transmitted, within the patients for whom the samples were received by the platforms
|
Throughout the study period, on average of 3 months
|
Delay time to send a validated exome sequencing report from signature to informed consent by the patient
Time Frame: an average of 8 weeks
|
The time delay between the date of informed consent signature and the date of dispatch of a validated MTB report to physician
|
an average of 8 weeks
|
The rate of patients with signed informed consent for whom a validated exome sequencing report is available
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom a report was transmitted, within the patients for whom signed consent has been signed
|
Throughout the study period, on average of 3 months
|
Delay time to receive sample on Platform from signature of informed consent
Time Frame: on average of 2 weeks
|
The time delay between the date of informed consent signature and the date of sample receipt on platform
|
on average of 2 weeks
|
The rate of patients with signed informed consent for whom samples have been received by platform
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom samples have been received by platform, within the patients for whom signed consent has been signed
|
Throughout the study period, on average of 3 months
|
Delay time to receipt nucleic acids on CNRGH from samples receipt on platform
Time Frame: on average of 1 week
|
The time delay between the date of sample receipt on platform and the date of nucleic acids receipt on CNRGH
|
on average of 1 week
|
The rate of patients with samples sending date completed on electronic case for whom samples have been received by platform
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom samples have been received by platform, within the patients for whom sending date has been completed on electronic case
|
Throughout the study period, on average of 3 months
|
The rate of patients with samples received on platform for whom these samples have been qualified in first step by platform and nucleic acids have been received by CNRGH
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom samples have been qualified in first step by platform and nucleic acids received by CNRGH, within the patients for whom samples have been received by platform
|
Throughout the study period, on average of 3 months
|
The rate of patients with samples received on Platform for whom these samples have been qualified in second step by platform and nucleic acids have been received by CNRGH
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom samples have been qualified in second step by platform and nucleic acids received by CNRGH, within the patients for whom samples have been received by platform
|
Throughout the study period, on average of 3 months
|
The rate of patients with samples received on platform for whom these samples have been qualified in first and second step by Platform and nucleic acids have been received by CNRGH
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom samples have been qualified in first and second step by platform and nucleic acids received by CNRGH, within the patients for whom samples have been received by platform
|
Throughout the study period, on average of 3 months
|
Delay time to receive all sequencing files from nucleic acids receipt on CNRGH
Time Frame: on average of 3 weeks
|
The time delay between the date of nucleic acids receipt on CNRGH and the date of receipt of all sequencing files by bioinformatic platform
|
on average of 3 weeks
|
The rate of patients with nucleic acids received on CNRGH for whom all sequencing files have been qualified by bioinformatics platform
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom all sequencing files have been qualified by bioinformatics platform, within the patients for whom samples have been received by CNRGH
|
Throughout the study period, on average of 3 months
|
The rate of patients with nucleic acids received on CNRGH for whom sequencing have been qualified by CNRGH
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom sequencing have been qualified by CNRGH, within the patients for whom samples have been received by CNRGH
|
Throughout the study period, on average of 3 months
|
Delay time to receive bioinformatics analysis for interpretation from availability of all sequencing files
Time Frame: on average of 1 week
|
The time delay between the date of receipt of all sequencing files by bioinformatics platform and the date of receipt of bioinformatics analysis by biologist for interpretation
|
on average of 1 week
|
The rate of patients with sequencing files received by bioinformatic Platform for whom these files have been qualified for analysis
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom all sequencing file have been qualified by bioinformatic platform, within the patients for whom all sequencing file have been received by bioinformatic platform
|
Throughout the study period, on average of 3 months
|
The rate of patients with sequencing files received by bioinformatic Platform for whom analysis have been transmitted for interpretation
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom bioinformatic analysis have been transmitted for interpretation, within the patients for whom all sequencing file have been received by bioinformatic platform
|
Throughout the study period, on average of 3 months
|
Delay time to send a validated exome sequencing report from availability of bioinformatic analysis
Time Frame: on average of 1 week
|
The time delay between the date of bioinformatic analysis availability for interpretation and the date of dispatch of a validated MTB report to physician
|
on average of 1 week
|
The rate of patients with bioinformatic analysis available for interpretation for whom biological interpretation has been performed
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom bioinformatic analysis has been interpreted by biologist, within the patients for whom bioinformatics analysis have been transmitted
|
Throughout the study period, on average of 3 months
|
The rate of patients with bioinformatic analysis available for interpretation for whom results has been discussed by MTB
Time Frame: Throughout the study period, on average of 3 months
|
Rate of patients for whom biological report has been discussed by MTB, within the patients for whom bioinformatics analysis have been transmitted
|
Throughout the study period, on average of 3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Sarcoma
- Colorectal Neoplasms
Other Study ID Numbers
- C17-11 MULTIPLI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
Clinical Trials on Next Generation Sequencing (NGS): exome, RNA seq
-
University Hospital, Strasbourg, FranceCompletedPrimary Immune-Deficiency (PID) Common Variable Immune Deficiency (CVID)France
-
Imperial College London Diabetes CentreUnknownDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Maturity-onset Diabetes of the YoungUnited Arab Emirates
-
Jagiellonian UniversityRecruiting
-
University Hospital TuebingenRecruitingRare Diseases | Genetic PredispositionGermany
-
Na Homolce HospitalCzech Academy of SciencesCompletedVascular AneurysmCzechia
-
Fudan UniversityUnknownColorectal Cancer | Lymph Node MetastasesChina
-
University Hospital TuebingenCharite University, Berlin, Germany; RWTH Aachen University; Medical University...Not yet recruiting
-
University Health Network, TorontoWomen's College Hospital; Jewish General Hospital; IWK Health Centre; British Columbia... and other collaboratorsRecruiting
-
Fudan UniversitySouthern Medical University, ChinaCompletedColorectal Cancer | AdenomaChina
-
Imperial College London Diabetes CentreUnknownFamilial HypercholesterolemiaUnited Arab Emirates